Analytical and Bioanalytical Chemistry

, Volume 400, Issue 10, pp 3481–3489 | Cite as

Drugs of abuse screening in urine as part of a metabolite-based LC-MSn screening concept

  • Dirk K. Wissenbach
  • Markus R. Meyer
  • Daniela Remane
  • Anika A. Philipp
  • Armin A. Weber
  • Hans H. Maurer
Original Paper

Abstract

Today, immunoassays and several chromatographic methods are in use for drug screening in clinical and forensic toxicology and in doping control. For further proof of the authors’ new metabolite-based liquid chromatography-mass spectrometry (LC-MSn) screening concept, the detectability of drugs of abuse and their metabolites using this screening approach was studied. As previously reported, the corresponding reference library was built up with MS2 and MS3 wideband spectra using a LXQ linear ion trap with electrospray ionization in the positive mode and full scan information-dependent acquisition. In addition to the parent drug spectra recorded in methanolic solution, metabolite spectra were identified after protein precipitation of urine from rats after administration of the corresponding drugs and added to the library. This consists now of data of over 900 parent compounds, including 87 drugs of abuse, and of over 2,300 metabolites and artifacts, among them 436 of drugs of abuse. Recovery, process efficiency, matrix effects, and limits of detection for selected drugs of abuse were determined using spiked human urine, and the resulting data have been acceptable. Using two automatic data evaluation tools (ToxID and SmileMS), the intake of 54 of the studied drugs of abuse could be confirmed in urine samples of drug users after protein precipitation and LC separation. The following drugs classes were covered: stimulants, designer drugs, hallucinogens, (synthetic) cannabinoids, opioids, and selected benzodiazepines. The presented LC-MSn method complements the well-established gas chromatography-mass spectroscopy procedure in the authors’ laboratory.

Keywords

Urine Screening LC-MS Library Metabolite Drugs of abuse 

Supplementary material

216_2011_5032_MOESM1_ESM.pdf (451 kb)
ESM 1(PDF 451 kb)

References

  1. 1.
    Kraemer T, Paul LD (2007) Anal Bioanal Chem 388:1415–1435CrossRefGoogle Scholar
  2. 2.
    Maurer HH (2006) J Mass Spectrom 41:1399–1413CrossRefGoogle Scholar
  3. 3.
    Maurer HH (2009) Anal Bioanal Chem 393:97–107CrossRefGoogle Scholar
  4. 4.
    Peters FT, Martinez-Ramirez JA (2010) Ther Drug Monit 32:532–539CrossRefGoogle Scholar
  5. 5.
    Tenore PL (2010) J Addict Dis 29:436–448CrossRefGoogle Scholar
  6. 6.
    Maurer HH (2007) Anal Bioanal Chem 388:1315–1325CrossRefGoogle Scholar
  7. 7.
    Peters FT (2010) Clin Biochem 44:54–65CrossRefGoogle Scholar
  8. 8.
    Josephs JL, Sanders M (2004) Rapid Commun Mass Spectrom 18:743–759CrossRefGoogle Scholar
  9. 9.
    Sauvage FL, Saint-Marcous F, Duretz B, Deporte D, Lachatre G, Marquet P (2006) Clin Chem 52:1735–1742CrossRefGoogle Scholar
  10. 10.
    Dulaurent S, Moesch C, Marquet P, Gaulier JM, Lachatre G (2010) Anal Bioanal Chem 396:2235–2249CrossRefGoogle Scholar
  11. 11.
    Sturm S, Hammann F, Drewe J, Maurer HH, Scholer A (2010) J Chromatogr B 878:2726–2732CrossRefGoogle Scholar
  12. 12.
    Mueller DM, Duretz B, Espourteille FA, Rentsch KM (2011) Anal Bioanal Chem 400:89–100CrossRefGoogle Scholar
  13. 13.
    Wissenbach DK, Meyer MR, Remane D, Weber AA, Maurer HH (2011) Anal Bioanal Chem 400:79–88CrossRefGoogle Scholar
  14. 14.
    Mueller CA, Weinmann W, Dresen S, Schreiber A, Gergov M (2005) Rapid Commun Mass Spectrom 19:1332–1338CrossRefGoogle Scholar
  15. 15.
    Dresen S, Gergov M, Politi L, Halter C, Weinmann W (2009) Anal Bioanal Chem 395:2521–2526CrossRefGoogle Scholar
  16. 16.
    Picard N, Dridi D, Sauvage FL, Boughattas NA, Marquet P (2009) J Sep Sci 32:2209–2217CrossRefGoogle Scholar
  17. 17.
    Sauvage FL, Picard N, Saint-Marcoux F, Gaulier JM, Lachatre G, Marquet P (2009) J Sep Sci 32:3074–3083CrossRefGoogle Scholar
  18. 18.
    Dresen S, Ferreiros N, Gnann H, Zimmermann R, Weinmann W (2010) Anal Bioanal Chem 396:2425–2434CrossRefGoogle Scholar
  19. 19.
    Viette V, Guillarme D, Mylonas R, Mauron Y, Fathi M, Rudaz S, Hochstrasser D, Veuthey JL (2011) Clin Biochem 44:32–44CrossRefGoogle Scholar
  20. 20.
    Viette V, Guillarme D, Mylonas R, Mauron Y, Fathi M, Rudaz S, Hochstrasser D, Veuthey JL (2011) Clin Biochem 44:45–53CrossRefGoogle Scholar
  21. 21.
    Gonzalez O, Alonso RM, Ferreiros N, Weinmann W, Zimmermann R, Dresen S (2011) J Chromatogr B Analyt Technol Biomed Life Sci 879:243–252CrossRefGoogle Scholar
  22. 22.
    Decaestecker TN, Vande C Sr, Wallemacq PE, Van Peteghem CH, Defore DL, Van Bocxlaer JF (2004) Anal Chem 76:6365–6373CrossRefGoogle Scholar
  23. 23.
    Pavlic M, Libiseller K, Oberacher H (2006) Anal Bioanal Chem 386:69–82CrossRefGoogle Scholar
  24. 24.
    Lee HK, Ho CS, Iu YP, Lai PS, Shek CC, Lo YC, Klinke HB, Wood M (2009) Anal Chim Acta 649:80–90CrossRefGoogle Scholar
  25. 25.
    Broecker S, Herre S, Wust B, Zweigenbaum J, Pragst F (2011) Anal Bioanal Chem 400:101–117CrossRefGoogle Scholar
  26. 26.
    Wohlfarth A, Weinmann W, Dresen S (2010) Anal Bioanal Chem 396:2403–2414CrossRefGoogle Scholar
  27. 27.
    Ristimaa J, Gergov M, Pelander A, Halmesmaki E, Ojanpera I (2010) Anal Bioanal Chem 398:925–935CrossRefGoogle Scholar
  28. 28.
    Kala SV, Harris SE, Freijo TD, Gerlich S (2008) J Anal Toxicol 32:605–611Google Scholar
  29. 29.
    Feng J, Wang L, Dai I, Harmon T, Bernert JT (2007) J Anal Toxicol 31:359–368Google Scholar
  30. 30.
    Duxbury K, Romagnoli C, Anderson M, Watts R, Waite G (2010) Ann Clin Biochem 47:415–422CrossRefGoogle Scholar
  31. 31.
    Bouzas NF, Dresen S, Munz B, Weinmann W (2009) Anal Bioanal Chem 395:2499–2507CrossRefGoogle Scholar
  32. 32.
    Baker DR, Kasprzyk-Hordern B (2011) J Chromatogr A 1218:1620–1631CrossRefGoogle Scholar
  33. 33.
    Bjork MK, Nielsen MK, Markussen LO, Klinke HB, Linnet K (2010) Anal Bioanal Chem 396:2393–2401CrossRefGoogle Scholar
  34. 34.
    Baselt RC (2009) Disposition of toxic drugs and chemicals in man. Biomedical Publications, Foster CityGoogle Scholar
  35. 35.
    Remane D, Meyer MR, Wissenbach DK, Maurer HH (2010) Rapid Commun Mass Spectrom 24:3103–3108CrossRefGoogle Scholar
  36. 36.
    Matuszewski BK, Constanzer ML, Chavez-Eng CM (2003) Anal Chem 75:3019–3030CrossRefGoogle Scholar
  37. 37.
    Hopley C, Bristow T, Lubben A, Simpson A, Bull E, Klagkou K, Herniman J, Langley J (2008) Rapid Commun Mass Spectrom 22:1779–1786CrossRefGoogle Scholar
  38. 38.
    Maurer HH, Pfleger K, Weber AA (2007) Mass spectral and GC data of drugs, poisons, pesticides, pollutants and their metabolites. Wiley-VCH, WeinheimGoogle Scholar
  39. 39.
    Philipp AA, Wissenbach DK, Zoerntlein SW, Klein ON, Kanogsunthornrat J, Maurer HH (2009) J Mass Spectrom 44:1249–1261CrossRefGoogle Scholar
  40. 40.
    Philipp AA, Wissenbach DK, Weber AA, Zapp J, Zoerntlein SW, Klein ON, Kanogsunthornrat J, Maurer HH (2010) Anal Bioanal Chem 396:2379–2391CrossRefGoogle Scholar
  41. 41.
    Philipp AA, Wissenbach DK, Weber AA, Zapp J, Maurer HH (2010) J Mass Spectrom 45:1344–1357CrossRefGoogle Scholar
  42. 42.
    Maurer HH, Pfleger K, Weber AA (2007) Mass spectral library of drugs, poisons, pesticides, pollutants and their metabolites. Wiley-VCH, WeinheimGoogle Scholar
  43. 43.
    Philipp AA, Wissenbach DK, Weber AA, Zapp J, Maurer HH (2011) Anal Bioanal Chem 399:2747–2753CrossRefGoogle Scholar
  44. 44.
    Meyer MR, Maurer HH (2010) Curr Drug Metab 11:468–482CrossRefGoogle Scholar
  45. 45.
    Paul LD, Musshoff F, Aebi B, Auwaerter V, Kraemer T, Peters FT, Skopp G, Aderjan R, Herbold M, Schmitt G, Thieme D, Toennes S (2009) Toxichem Krimtech 76:142–176 (http://www.gtfch.org/cms/index.php/guidelines)Google Scholar
  46. 46.
    Li AC, Gohdes MA, Shou WZ (2007) Rapid Commun Mass Spectrom 21:1421–1430CrossRefGoogle Scholar
  47. 47.
    Rivier L (2003) Anal Chim Acta 492:69–82CrossRefGoogle Scholar
  48. 48.
    Balikova M (2005) Forensic Sci Int 153:85–91CrossRefGoogle Scholar
  49. 49.
    Beyer J, Ehlers D, Maurer HH (2006) Ther Drug Monit 28:568–575CrossRefGoogle Scholar
  50. 50.
    Staack RF, Fritschi G, Maurer HH (2002) J Chromatogr B Analyt Technol Biomed Life Sci 773:35–46CrossRefGoogle Scholar
  51. 51.
    Staack RF, Maurer HH (2003) J Anal Toxicol 27:560–568Google Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Dirk K. Wissenbach
    • 1
  • Markus R. Meyer
    • 1
  • Daniela Remane
    • 1
  • Anika A. Philipp
    • 1
  • Armin A. Weber
    • 1
  • Hans H. Maurer
    • 1
  1. 1.Department of Experimental and Clinical Toxicology, Institute of Experimental and Clinical Pharmacology and ToxicologySaarland UniversityHomburg (Saar)Germany

Personalised recommendations